

agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. *J Neurosci* 2003; 23:876-82

3. Todd MM: Anesthetic neurotoxicity: The collision between laboratory neuroscience and clinical medicine. *ANESTHESIOLOGY* 2004; 101:533-4

4. Bohnen N, Warner MA, Kokmen E, Kurland LT: Early and midlife exposure to anesthesia and age of onset of Alzheimer's disease. *Int J Neurosci* 1994; 77:181-5

5. Eckenhoff RG, Johansson JS, Wei H, Carnini A, Kang B, Wei W, Pidikiti R, Keller JM, Eckenhoff MF: Inhaled anesthetic enhancement of amyloid- β oligomerization and cytotoxicity. *ANESTHESIOLOGY* 2004; 101:703-9

6. Xie Z, Dong Y, Maeda U, Moir RD, Xia W, Culley DJ, Crosby G, Tanzi RE: The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. *J Neurosci* 2007; 27:1247-54

7. Culley DJ, Yukhananov RY, Xie Z, Gali RR, Tanzi RE, Crosby G: Altered hippocampal gene expression 2 days after general anesthesia in rats. *Eur J Pharmacol* 2006; 549:71-8

8. Rabinowicz T, de Courten-Myers GM, Petetot JM, Xi G, de los Reyes E: Human cortex development: Estimates of neuronal numbers indicate major loss late during gestation. *J Neuropathol Exp Neurol* 1996; 55:320-8

9. Mellon RD, Simone AF, Rappaport BA: Use of anesthetic agents in neonates and young children. *Anesth Analg* 2007; 104:509-20

10. Scallet AC, Schmued LC, Slikker W Jr, Grunberg N, Faustino PJ, Davis H, Lester D, Pine PS, Sistare F, Hanig JP: Developmental neurotoxicity of ketamine: Morphometric confirmation, exposure parameters, and multiple fluorescent labeling of apoptotic neurons. *Toxicol Sci* 2004; 81:364-70

11. Yon JH, Daniel-Johnson J, Carter IB, Jevtovic-Todorovic V: Anesthesia induces neuronal cell death in the developing rat brain *via* the intrinsic and extrinsic apoptotic pathways. *Neuroscience* 2005; 135:815-27

12. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Voelcker J, Dikranian K, Tenkova TI, Stefovskva V, Turski L, Olney JW: Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. *Science* 1999; 283:70-4

13. Wang C, Sadovova N, Fu X, Schmued L, Scallet A, Hanig J, Slikker W: The role of the N-methyl-D-aspartate receptor in ketamine-induced apoptosis in rat forebrain culture. *Neuroscience* 2005; 132:967-77

14. Yahashi H, Dikkes P, Soriano SG: Repeated administration of ketamine may lead to neuronal degeneration in the developing rat brain. *Paediatr Anaesth* 2002; 12:770-4

15. Wang C, Sadovova N, Hotchkiss C, Fu X, Scallet AC, Patterson TA, Hanig J, Paule MG, Slikker W Jr: Blockade of N-methyl-D-aspartate receptors by ket-

amine produces loss of postnatal day 3 monkey frontal cortical neurons in culture. *Toxicol Sci* 2006; 91:192-201

16. Slikker W, Zou X, Hotchkiss CE, Divine RL, Sadovova N, Twaddle NC, Doerge DR, Scallet AC, Patterson TA, Hanig J, Paule MG, Wang C: Ketamine-induced neuronal cell death in the perinatal rhesus monkey [published on-line ahead of print April 10, 2007]. *Toxicol Sci* 2007. doi:10.1093/toxsci/kfm084

17. Young C, Jevtovic-Todorovic V, Qin YQ, Tenkova T, Wang H, Labruyere J, Olney JW: Potential of ketamine and midazolam, individually or in combination, to induce apoptotic neurodegeneration in the infant mouse brain. *Br J Pharmacol* 2005; 146:189-97

18. Fredriksson A, Archer T, Alm H, Gordh T, Eriksson P: Neurofunctional deficits and potentiated apoptosis by neonatal NMDA antagonist administration. *Behav Brain Res* 2004; 153:367-76

19. Clancy B, Finlay BL, Darlington RB, Anand KJS: Extrapolating brain development from experimental species to humans [published on-line ahead of print February 15, 2007]. *Neurotoxicology* 2007. PMID: 17368774

20. Anand KJS, Garg S, Rovnaghi CR, Narsinghani U, Bhutta AT, Hall RW: Ketamine reduces the cell death following inflammatory pain in newborn rat brain. *Pediatr Res* 2007; 62:1-8

21. O'Rahilly R, Muller F: Minireview: Summary of the initial development of the human nervous system. *Teratology* 1999; 60:39-41

22. Muller F, O'Rahilly R: The timing and sequence of appearance of neuromeres and their derivatives in staged human embryos. *Acta Anatomica* 1997; 158:83-99

23. Bayer SA, Altman J: Development of layer I and the subplate in the rat neocortex. *Exp Neurol* 1990; 107:48-62

24. Bayer SA, Altman J, Russo RJ, Zhang X: Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. *Neurotoxicology* 1993; 14:83-144

25. Dobbing J: Undernutrition and the developing brain: The relevance of animal models to the human problem. *Am J Dis Child* 1970; 120:411-5

26. Dobbing J, Sands J: Vulnerability of developing brain not explained by cell number/cell size hypothesis. *Early Hum Dev* 1981; 5:227-31

27. Dobbing J, Sands J: Comparative aspects of the brain growth spurt. *Early Hum Dev* 1979; 3:79-83

28. de Graaf-Peters VB, Hadders-Algra M: Ontogeny of the human central nervous system: What is happening when? *Early Hum Dev* 2006; 82:257-66

Anesthesiology 2007; 107:4-5

Copyright © 2007, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc.

Ethnicity Can Affect Anesthetic Requirement

LABORATORY investigations in model organisms show that changes in genes can influence inhaled anesthetic requirement. For example, in *Caenorhabditis elegans*, mutations in *unc-1/stomatin*¹ and *syntaxin*² affect anesthetic requirement; in *Drosophila*, alterations in genes coding for particular ABC transporters can affect responses to anesthetic³; in mice, mutations in glycine receptors,⁴ two-pore domain potassium channels,⁵ and *stomatin*¹ change minimum alveolar concentration (MAC). These genetic modifications are by and large engineered into animals to discover how anesthetics work, and have little immediate relevance to the conduct of clinical anesthesia in humans. But even in normal healthy populations, there is evidence of genetic influences on anesthetic requirement. Among inbred laboratory mice, MAC varies depending on the strain.⁶ Red-

headed human patients have a higher MAC than other patients,⁷ probably either because variants of genes that govern hair color (*e.g.*, *melanocortin*⁸) affect MAC, or genes closely linked to those determining hair color affect MAC. In this issue of *ANESTHESIOLOGY*, Ezri *et al.*⁹ build on this background and show that ethnicity can influence MAC.

These investigators determined sevoflurane MAC in three ethnic groups of Jewish patients undergoing surgery: European Jews, Oriental Jews, and Jews from the Caucasus Mountain region. The patients were demographically similar except for ethnicity. They found that MAC between groups varied by up to 24%, with European Jews having the lowest MAC, Caucasian Jews having the highest MAC, and Oriental Jews being in between.

What can account for this variability? In broad terms, the variability may be (1) technical, *e.g.*, from measurement error; (2) genetic, as discussed above; (3) nongenetic but biologic, a category that includes many well-known factors affecting MAC such as temperature, pregnancy, circadian rhythms, and age; (4) environmental factors such as drug use and diet; and (5) gene-environment interactions, which may be important to many disease and behavioral phenotypes. Ezri *et al.*⁹ are circumspect in ascribing a biologic basis for their observations. But by performing a

This Editorial View accompanies the following article: Ezri T, Sessler D, Weisenberg M, Muzikant G, Protianov M, Mascha E, Evron S: Association of ethnicity with the minimum alveolar concentration of sevoflurane. *ANESTHESIOLOGY* 2007; 107:9-14.

Accepted for publication March 15, 2007. The author is not supported by, nor maintains any financial interest in, any commercial activity that may be associated with the topic of this article.

blinded study with the same investigators at a single hospital, they have greatly reduced the possibility of systematic technical errors. Similarly, by studying patients at the same time of day, excluding pregnant patients, and excluding patients with a history of chronic pain or analgesic or sedative drug use, they eliminated several potential confounders. In fact, by carefully limiting sources of variability, they make a reasonable case for a genetic basis for the described ethnic differences in MAC, although, as they note, this will require further study.

Let us suppose that different variants (alleles) of genes that are important to MAC are indeed present in the three ethnic groups studied and account at least in part for the difference in MAC that was found. Can the MAC differences in these populations be used to identify these genes? Using traditional approaches, probably not. These approaches use either linkage analysis or a candidate gene approach. Linkage analysis is used to identify alleles of genes associated with higher or lower values of phenotype such as MAC. This would require a pedigree of related individuals with different MACs, rather than groups of unrelated individuals, a pedigree that has never been identified. Candidate gene studies use a knowledge of biochemistry and physiology to identify genes that may plausibly affect phenotype. This technique is best pursued in animals rather than in humans, where genes can be manipulated and their effect can be measured directly. Indeed, this approach has been actively pursued in mice in studies of inhaled anesthetic mechanisms for approximately a decade, with mixed results.¹⁰

The study by Ezri *et al.*⁹ nonetheless arrives at a propitious time. New techniques, based on recent advances in genomics, can now be applied to populations of unrelated individuals to identify the genetic basis for phenotypic (*e.g.*, MAC) differences. Two developments have enabled this to happen. The first is DNA array technology, permitting rapid, accurate identification of single nucleotide differences in DNA sequences (called *single nucleotide polymorphisms* [SNPs]). Current commercially available technology allows the genotyping of hundreds of thousands of SNPs per subject. The second is the work of the International HapMap project.¹¹ This consortium seeks to group adjoining SNPs that are inherited together into blocks called *haplotypes*. The theoretical reason for doing this is that cataloging haplotypes should ultimately permit patterns of inheritance of genetic variants that underlie drug and disease susceptibility to be identified. Practically, this knowledge reduces the amount of genotyping required in any gene association study: Because SNPs within a haplotype are inherited together, only one SNP need be genotyped for each haplotype. Of note to the study by Ezri *et al.*,⁹ these haplotypes are identified by SNP genotyping of individuals from different ethnic groups.

These technologies enable a conceptually simple study design. First, measure MAC in a large number of subjects.

Second, exhaustively genotype subjects at one SNP per haplotype block. Third, determine which haplotype blocks are associated with higher and lower MAC: Genes within those haplotype blocks should underlie the difference in MAC in the study population. A recent genome-wide association study of type 2 diabetes mellitus¹² provides a proof of principle for this type of investigation. In this study, almost 1,400 subjects (affected individuals plus controls) were studied. Subjects were genotyped at approximately 400,000 unique SNPs. The study confirmed an association with a previously identified zinc transporter. More importantly, it found associations with another zinc transporter expressed only in the secretory vesicles of insulin-producing β cells, and two haplotype blocks containing genes involved in pancreatic development. The finding of new genes whose variants affect the development of type 2 diabetes mellitus illustrates the power of genome-wide association studies. Although the logistic issues of performing such a study with inhaled anesthetics would be formidable, the identification of ethnic groups with differences in MAC opens the door to identifying genes determining anesthetic sensitivity *via* a genome-wide association study in humans.

James M. Sonner, M.D., Department of Anesthesia and Perioperative Care, University of California, San Francisco, California. sonnerj@anesthesia.ucsf.edu

References

1. Sedensky MM, Pujazon MA, Morgan PG: Tail clamp responses in stomatin knockout mice compared with mobility assays in *Caenorhabditis elegans* during exposure to diethyl ether, halothane, and isoflurane. *ANESTHESIOLOGY* 2006; 105:498-502
2. van Swinderen B, Saifee O, Shebestler L, Roberson R, Nonet ML, Crowder CM: A neomorphic syntaxin mutation blocks volatile-anesthetic action in *Caenorhabditis elegans*. *Proc Natl Acad Sci U S A* 1999; 96:2479-84
3. Campbell JL, Nash HA: Volatile general anesthetics reveal a neurobiological role for the white and brown genes of *Drosophila melanogaster*. *J Neurobiol* 2001; 49:339-49
4. Quinlan JJ, Ferguson C, Jester K, Firestone LL, Homanics GE: Mice with glycine receptor subunit mutations are both sensitive and resistant to volatile anesthetics. *Anesth Analg* 2002; 95:578-82
5. Franks NP, Honore E: The TREK K2P channels and their role in general anaesthesia and neuroprotection. *Trends Pharmacol Sci* 2004; 25:601-8
6. Sonner JM, Gong D, Eger EI II: Naturally occurring variability in anesthetic potency among inbred mouse strains. *Anesth Analg* 2000; 91:720-6.
7. Liem EB, Lin CM, Suleman MI, Doufas AG, Gregg RG, Veauthier JM, Loyd G, Sessler D: Anesthetic requirement is increased in redheads. *ANESTHESIOLOGY* 2004; 101:279-83
8. Xing Y, Sonner JM, Eger EI II, Cascio M, Sessler DI: Mice with a melanocortin 1 receptor mutation have a slightly greater minimum alveolar concentration than control mice. *ANESTHESIOLOGY* 2004; 101:544-6
9. Ezri T, Sessler D, Weisenberg M, Muzikant G, Protianov M, Mascha E, Evron S: Association of ethnicity with the minimum alveolar concentration of sevoflurane. *ANESTHESIOLOGY* 2007; 107:9-14
10. Sonner JM, Werner DF, Elsen FP, Xing Y, Liao M, Harris RA, Harrison NL, Fanselow MS, Eger EI II, Homanics GE: Effect of isoflurane and other potent inhaled anesthetics on minimum alveolar concentration, learning, and the righting reflex in mice engineered to express α_1 γ -aminobutyric acid type A receptors unresponsive to isoflurane. *ANESTHESIOLOGY* 2007; 106:107-13
11. International HapMap Consortium: A haplotype map of the human genome. *Nature* 2005; 437:1299-320
12. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent D, Belisle A, Hadjadj S, Balkau B, Heude B, Charpentier G, Hudson TJ, Montetit A, Pshzhetsky AV, Prentki M, Posner BI, Balding DJ, Meyre D, Polychronakos C, Froguel P: A genome-wide association study identifies novel risk loci for type 2 diabetes. *Nature* 2007; 445:881-5